MA31624B1 - Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion - Google Patents
Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusionInfo
- Publication number
- MA31624B1 MA31624B1 MA32638A MA32638A MA31624B1 MA 31624 B1 MA31624 B1 MA 31624B1 MA 32638 A MA32638 A MA 32638A MA 32638 A MA32638 A MA 32638A MA 31624 B1 MA31624 B1 MA 31624B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- indirect
- ischemia
- prophylaxis
- cardiac
- Prior art date
Links
- 108010092464 Urate Oxidase Proteins 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 229940005267 urate oxidase Drugs 0.000 title abstract 3
- 230000010410 reperfusion Effects 0.000 title abstract 2
- 208000020446 Cardiac disease Diseases 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 208000028867 ischemia Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 238000013146 percutaneous coronary intervention Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 238000007675 cardiac surgery Methods 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 108010084837 rasburicase Proteins 0.000 abstract 1
- 229960000424 rasburicase Drugs 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
L'INVENTION CONCERNE L'UTILISATION D'UNE URATE-OXYDASE, DE PRÉFÉRENCE UNE URATE-OXYDASE RECOMBINÉE, LA RASBURICASE PAR EXEMPLE, DANS LA PRODUCTION D'UN MÉDICAMENT DESTINÉ À LA PRÉVENTION OU AU TRAITEMENT DE TROUBLES OU DE SÉQUELLES INDIRECTES CARDIAQUES CAUSÉS PAR DES ÉVÉNEMENTS ISCHÉMIQUES OU DE REPERFUSION, PAR EXEMPLE PENDANT ET APRÈS UNE INTERVENTION DE CHIRURGIE CARDIAQUE TELLE QU'UN PONTAGE AORTOCORONARIEN, UNE INTERVENTION CORONARIENNE PERCUTANÉE (ICP), UNE TRANSPLANTATION, APRÈS UN INFARCTUS DU MYOCARDE ET DANS LA PRÉVENTION OU LE TRAITEMENT DE LA CORONAROPATHIE OU DE L'INSUFFISANCE CARDIAQUE, DE L'INSUFFISANCE CARDIAQUE CONGESTIVE PAR EXEMPLE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291072 | 2007-09-05 | ||
| US1524007P | 2007-12-20 | 2007-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31624B1 true MA31624B1 (fr) | 2010-08-02 |
Family
ID=38713162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32638A MA31624B1 (fr) | 2007-09-05 | 2010-02-22 | Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100266567A1 (fr) |
| EP (1) | EP2197550A1 (fr) |
| JP (1) | JP2011509920A (fr) |
| KR (1) | KR20100053609A (fr) |
| CN (1) | CN101801460A (fr) |
| AR (1) | AR068360A1 (fr) |
| AU (1) | AU2008295145B2 (fr) |
| BR (1) | BRPI0816406A2 (fr) |
| CA (1) | CA2697929A1 (fr) |
| CL (1) | CL2008002623A1 (fr) |
| CO (1) | CO6260090A2 (fr) |
| IL (1) | IL204259A (fr) |
| MA (1) | MA31624B1 (fr) |
| MX (1) | MX2010001976A (fr) |
| MY (1) | MY183770A (fr) |
| NZ (1) | NZ583635A (fr) |
| PA (1) | PA8794801A1 (fr) |
| PE (1) | PE20090642A1 (fr) |
| TW (1) | TW200927929A (fr) |
| UY (1) | UY31320A1 (fr) |
| WO (1) | WO2009030373A1 (fr) |
| ZA (1) | ZA201000774B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013082458A1 (fr) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Solution de protection de reperfusion et ses utilisations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114972A (en) * | 1990-07-30 | 1992-05-19 | Tsuyoshi Ohnishi | Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities |
| AU2001268734A1 (en) * | 2000-06-28 | 2002-01-08 | Merck & Co., Inc. | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| US20040132666A1 (en) * | 2002-09-20 | 2004-07-08 | Oregon Health & Science University | Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| JP5010923B2 (ja) * | 2004-02-09 | 2012-08-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合蛋白質 |
| WO2005099758A2 (fr) * | 2004-04-17 | 2005-10-27 | The Board Of Trustees The Leland Standford Junior University | Matrice de tissu bioartificielle injectable |
| US20070197512A1 (en) * | 2006-01-27 | 2007-08-23 | Japan Tobacco Inc. | Carboxylic Acid Compounds and Use Thereof |
-
2008
- 2008-08-20 EP EP08785655A patent/EP2197550A1/fr not_active Withdrawn
- 2008-08-20 WO PCT/EP2008/006858 patent/WO2009030373A1/fr not_active Ceased
- 2008-08-20 CN CN200880105379A patent/CN101801460A/zh active Pending
- 2008-08-20 NZ NZ583635A patent/NZ583635A/en not_active IP Right Cessation
- 2008-08-20 BR BRPI0816406A patent/BRPI0816406A2/pt not_active IP Right Cessation
- 2008-08-20 AU AU2008295145A patent/AU2008295145B2/en not_active Ceased
- 2008-08-20 MX MX2010001976A patent/MX2010001976A/es active IP Right Grant
- 2008-08-20 KR KR1020107004878A patent/KR20100053609A/ko not_active Ceased
- 2008-08-20 MY MYPI2010000585A patent/MY183770A/en unknown
- 2008-08-20 CA CA2697929A patent/CA2697929A1/fr not_active Abandoned
- 2008-08-20 JP JP2010523299A patent/JP2011509920A/ja active Pending
- 2008-09-03 UY UY31320A patent/UY31320A1/es not_active Application Discontinuation
- 2008-09-03 AR ARP080103828A patent/AR068360A1/es not_active Application Discontinuation
- 2008-09-03 PA PA20088794801A patent/PA8794801A1/es unknown
- 2008-09-03 TW TW097133674A patent/TW200927929A/zh unknown
- 2008-09-03 PE PE2008001545A patent/PE20090642A1/es not_active Application Discontinuation
- 2008-09-04 CL CL2008002623A patent/CL2008002623A1/es unknown
-
2010
- 2010-02-02 ZA ZA2010/00774A patent/ZA201000774B/en unknown
- 2010-02-22 MA MA32638A patent/MA31624B1/fr unknown
- 2010-02-24 CO CO10021841A patent/CO6260090A2/es not_active Application Discontinuation
- 2010-03-01 US US12/715,061 patent/US20100266567A1/en not_active Abandoned
- 2010-03-02 IL IL204259A patent/IL204259A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL204259A (en) | 2013-06-27 |
| CA2697929A1 (fr) | 2009-03-12 |
| US20100266567A1 (en) | 2010-10-21 |
| TW200927929A (en) | 2009-07-01 |
| KR20100053609A (ko) | 2010-05-20 |
| JP2011509920A (ja) | 2011-03-31 |
| NZ583635A (en) | 2011-06-30 |
| CN101801460A (zh) | 2010-08-11 |
| UY31320A1 (es) | 2009-04-30 |
| CL2008002623A1 (es) | 2009-01-16 |
| BRPI0816406A2 (pt) | 2017-05-16 |
| AU2008295145A1 (en) | 2009-03-12 |
| CO6260090A2 (es) | 2011-03-22 |
| MX2010001976A (es) | 2010-03-10 |
| WO2009030373A1 (fr) | 2009-03-12 |
| AR068360A1 (es) | 2009-11-11 |
| PA8794801A1 (es) | 2009-04-23 |
| MY183770A (en) | 2021-03-12 |
| ZA201000774B (en) | 2011-04-28 |
| RU2010112867A (ru) | 2011-10-10 |
| EP2197550A1 (fr) | 2010-06-23 |
| PE20090642A1 (es) | 2009-06-18 |
| AU2008295145B2 (en) | 2013-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0713350A2 (pt) | inibidores de prolil hidroxilase e métodos de utilização | |
| EP3986863A4 (fr) | Inhibiteurs de glycolate oxydase pour le traitement d'une maladie | |
| NZ600400A (en) | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | |
| MA30806B1 (fr) | Phosphoindoles enantiomeriquement purs utilisables en tant qu'inhibiteurs du vih | |
| WO2008132138A9 (fr) | Dérivés d'aminopyrimidines disubstituées en 4 et en 6 | |
| TNSN03083A1 (en) | Mercaptoacetylamide derivatives, a process for their preparation and their use | |
| MA30478B1 (fr) | Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia. | |
| EP4301132A4 (fr) | Inhibiteur de rock2 pour le traitement d'une infection virale | |
| EP1358868A3 (fr) | Composition cosmétique pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux | |
| NO335813B1 (no) | Kombinasjon omfattende kandesartan eller et farmasøytisk akseptabelt salt derav og rosuvastatin eller et farmasøytisk akseptabelt salt derav for forebygging eller behandling av sykdom | |
| WO2009005838A3 (fr) | Procédé de préparation d'une solution basique non corrosive et ses procédés d'utilisation | |
| JP2017530954A5 (fr) | ||
| US20090075976A1 (en) | Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor | |
| MA28081A1 (fr) | Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire | |
| IL204259A (en) | Use of resburicase to prepare a drug to treat or prevent heart disease or heart problems caused by previous events or blockage of blood flow to the heart | |
| MX2018005359A (es) | Pirroloisoindolonas nuevos inhibidores de la enzima convertidora de angiotensina (iecas) para el tratamiento de la hipertension arterial. | |
| TH104398B (th) | การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด | |
| JP2010513300A5 (fr) | ||
| EE200300500A (et) | Merkaptoatsetüülamiidi derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja selle valmistamismeetod | |
| Vivas et al. | Atrial Fibrillation and Anticoagulation Therapy–Different Race, Different Risk, and Different Management?– | |
| CA3156303A1 (fr) | Derives de 5-fluoronicotinamide et leurs utilisations | |
| EP3981423A4 (fr) | Composition pour la prévention ou le traitement d'une maladie liée à l'acide urique | |
| FR3128872B1 (fr) | Nouvelles combinaisons synergiques a base de fenm | |
| CA2705300A1 (fr) | Macrocyclic inhibitors of hepatitis c protease | |
| Kuzmanic et al. | Polymorphism of angiotensin-converting enzyme in patients with primary glomerulonephritis and hypertension |